Raymond W Cohen Axonics, Inc. (AXNX) insider trading activity

Raymond W Cohen is Chief Executive Officer of Axonics, Inc.. Currently has a direct ownership of 188,835 shares of AXNX, which is worth approximately $12.7 Million. The most recent transaction as insider was on Jan 31, 2024, when has been sold 35,161 shares (Common Stock) at a price of $67.74 per share, resulting in proceeds of $2,381,806. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 189K

0% 3M change

17.58% 12M change

Total Value Held $12.7 Million

RAYMOND W COHEN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 31 2024	SELL Open market or private sale	$2,381,806 $67.74 p/Share	35,161 Reduced 15.7%	188,835 Common Stock
Jan 31 2024	BUY Exercise of conversion of derivative security	-	63,400 Added 22.06%	223,996 Common Stock
Feb 01 2023	SELL Open market or private sale	$492,945 $60.73 p/Share	8,117 Reduced 4.81%	160,596 Common Stock
Jan 31 2023	SELL Open market or private sale	$1,400,350 $61.14 p/Share	22,904 Reduced 11.95%	168,713 Common Stock
Jan 31 2023	BUY Exercise of conversion of derivative security	-	61,968 Added 24.44%	191,617 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	20,750 Added 13.8%	129,649 Common Stock
Jan 13 2023	SELL Open market or private sale	$2,684,502 $65.9 p/Share	40,736 Reduced 27.22%	108,899 Common Stock

Aug 08 2022	SELL Open market or private sale	$3,120,040 $70.91 p/Share	44,000 Reduced 22.72%	149,635 Common Stock
Mar 29 2022	SELL Open market or private sale	$3,000,000 $60.0 p/Share	50,000 Reduced 20.52%	193,635 Common Stock
Mar 14 2022	SELL Open market or private sale	$2,632,500 $52.65 p/Share	50,000 Reduced 17.03%	243,635 Common Stock
Feb 03 2022	SELL Open market or private sale	$1,707,291 $48.62 p/Share	35,115 Reduced 9.37%	339,635 Common Stock
Feb 03 2022	BUY Exercise of conversion of derivative security	-	96,846 Added 20.54%	374,750 Common Stock
Jan 31 2022	BUY Grant, award, or other acquisition	-	43,297 Added 13.48%	277,904 Common Stock
Sep 09 2021	SELL Open market or private sale	$3,855,500 $77.11 p/Share	50,000 Reduced 17.57%	234,607 Common Stock
Jun 08 2021	SELL Open market or private sale	$1,999,980 $60.0 p/Share	33,333 Reduced 10.48%	284,607 Common Stock
May 18 2021	SELL Open market or private sale	$1,805,815 $55.0 p/Share	32,833 Reduced 9.36%	317,940 Common Stock
May 10 2021	SELL Open market or private sale	$1,825,967 $53.97 p/Share	33,833 Reduced 8.8%	350,773 Common Stock
Feb 01 2021	SELL Open market or private sale	$705,061 $51.74 p/Share	13,627 Reduced 2.9%	456,096 Common Stock
Feb 01 2021	BUY Exercise of conversion of derivative security	-	33,334 Added 6.63%	469,723 Common Stock
Jan 31 2021	BUY Grant, award, or other acquisition	-	20,000 Added 4.38%	436,389 Common Stock
Jan 26 2021	SELL Open market or private sale	$420,174 $53.58 p/Share	7,842 Reduced 1.85%	416,389 Common Stock
Jan 26 2021	BUY Exercise of conversion of derivative security	-	27,173 Added 6.02%	424,231 Common Stock

Also insider at

BLFS

BIOLIFE SOLUTIONS INC Healthcare

Director

RWC

Raymond W Cohen

Chief Executive Officer

Irvine, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AXNX shares.

Notify only if

Value

Insider Trading

Get notified when an Axonics, Inc. insider buys or sells AXNX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Axonics, Inc.

Track Activities on AXNX

Account